Sarepta Tax Provision vs Non Recurring Analysis
SRPT Stock | USD 130.83 0.55 0.42% |
Sarepta Therapeutics financial indicator trend analysis is much more than just breaking down Sarepta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sarepta Therapeutics is a good investment. Please check the relationship between Sarepta Therapeutics Tax Provision and its Non Recurring accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.
Tax Provision vs Non Recurring
Tax Provision vs Non Recurring Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sarepta Therapeutics Tax Provision account and Non Recurring. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Sarepta Therapeutics' Tax Provision and Non Recurring is 0.54. Overlapping area represents the amount of variation of Tax Provision that can explain the historical movement of Non Recurring in the same time period over historical financial statements of Sarepta Therapeutics, assuming nothing else is changed. The correlation between historical values of Sarepta Therapeutics' Tax Provision and Non Recurring is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tax Provision of Sarepta Therapeutics are associated (or correlated) with its Non Recurring. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Recurring has no effect on the direction of Tax Provision i.e., Sarepta Therapeutics' Tax Provision and Non Recurring go up and down completely randomly.
Correlation Coefficient | 0.54 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Non Recurring
Most indicators from Sarepta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sarepta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.At this time, Sarepta Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 30.6 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (35.04).
2023 | 2024 (projected) | Non Recurring | 199.2M | 209.2M | Interest Income | 67.7M | 71.0M |
Sarepta Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Sarepta Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sarepta Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.8B | 3.0B | 3.1B | 3.1B | 3.3B | 3.4B | |
Other Current Liab | 196.7M | 22.1M | 15.1M | 419.0M | 315.0M | 330.7M | |
Total Current Liabilities | 264.8M | 416.0M | 452.7M | 619.6M | 653.7M | 686.3M | |
Total Stockholder Equity | 818.2M | 761.8M | 928.0M | 385.0M | 859.3M | 902.3M | |
Property Plant And Equipment Net | 167.6M | 282.2M | 236.7M | 245.0M | 357.1M | 375.0M | |
Net Debt | (105.5M) | (429.8M) | (977.5M) | 650.6M | 968.4M | 1.0B | |
Retained Earnings | (2.3B) | (2.8B) | (3.2B) | (3.9B) | (4.4B) | (4.2B) | |
Accounts Payable | 68.1M | 111.1M | 76.7M | 95.9M | 164.9M | 173.2M | |
Cash | 835.1M | 1.5B | 2.1B | 966.8M | 428.4M | 298.4M | |
Non Current Assets Total | 353.9M | 499.5M | 543.9M | 570.5M | 685.2M | 719.5M | |
Non Currrent Assets Other | 11.8M | 13.0M | 143.3M | 286.6M | 276.4M | 290.2M | |
Cash And Short Term Investments | 1.1B | 1.9B | 2.1B | 2.0B | 1.7B | 1.8B | |
Common Stock Total Equity | 6K | 7K | 8K | 9K | 8.1K | 7.7K | |
Common Stock Shares Outstanding | 73.6M | 78.0M | 81.3M | 87.6M | 92.4M | 97.0M | |
Short Term Investments | 803.1M | 289.7M | 435.9M | 1.0B | 1.2B | 1.3B | |
Liabilities And Stockholders Equity | 1.8B | 3.0B | 3.1B | 3.1B | 3.3B | 3.4B | |
Other Stockholder Equity | 3.1B | 3.6B | 4.1B | 4.3B | 5.3B | 5.6B | |
Total Liab | 1.0B | 2.2B | 2.2B | 2.7B | 2.4B | 2.5B | |
Property Plant And Equipment Gross | 167.6M | 282.2M | 349.3M | 393.9M | 548.1M | 575.5M | |
Total Current Assets | 1.5B | 2.5B | 2.6B | 2.6B | 2.6B | 2.7B | |
Accumulated Other Comprehensive Income | 50K | 3K | (20K) | (1.7M) | 918K | 963.9K | |
Intangible Assets | 12.5M | 13.6M | 14.2M | 7.6M | 29.6M | 31.1M | |
Common Stock | 6K | 7K | 8K | 9K | 8.1K | 7.7K | |
Non Current Liabilities Total | 739.9M | 1.8B | 1.8B | 2.1B | 1.8B | 1.8B | |
Other Current Assets | 5.2M | 4.1M | 6.1M | 7.7M | 140.5M | 147.5M | |
Other Assets | 141.9M | 295.5M | 292.9M | 286.6M | 1.0 | 0.95 | |
Property Plant Equipment | 129.6M | 190.4M | 191.2M | 245.0M | 281.7M | 295.8M | |
Net Receivables | 93.9M | 138.6M | 171.6M | 259.7M | 439.7M | 461.7M | |
Short Long Term Debt Total | 729.6M | 1.1B | 1.1B | 1.6B | 1.4B | 1.5B | |
Other Liab | 10.2M | 734.1M | 628.8M | 521.9M | 600.2M | 630.2M | |
Long Term Debt | 681.9M | 992.5M | 1.1B | 1.5B | 1.1B | 1.2B | |
Short Term Debt | 7.8M | 193.6M | 271.7M | 15.5M | 123.3M | 129.5M | |
Net Tangible Assets | 805.7M | 748.1M | 913.8M | 377.4M | 434.0M | 530.3M | |
Retained Earnings Total Equity | (1.6B) | (2.3B) | (2.8B) | (3.2B) | (2.9B) | (2.7B) | |
Long Term Debt Total | 420.6M | 681.9M | 992.5M | 1.1B | 1.3B | 1.3B | |
Capital Surpluse | 2.6B | 3.1B | 3.6B | 4.1B | 4.8B | 5.0B | |
Inventory | 171.4M | 232.0M | 186.2M | 204.0M | 322.9M | 339.0M |
Pair Trading with Sarepta Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sarepta Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarepta Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sarepta Stock
0.46 | EXEL | Exelixis | PairCorr |
The ability to find closely correlated positions to Sarepta Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sarepta Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sarepta Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sarepta Therapeutics to buy it.
The correlation of Sarepta Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sarepta Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sarepta Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sarepta Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.43 | Revenue Per Share 14.953 | Quarterly Revenue Growth 0.631 | Return On Assets (0.02) | Return On Equity 0.0202 |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.